|1.||Camilleri, M: 9 articles (02/2007 - 01/2000)|
|2.||Chang, Lin: 8 articles (11/2013 - 10/2002)|
|3.||Chey, William D: 6 articles (11/2013 - 01/2003)|
|4.||Carter, Eric G: 4 articles (08/2007 - 08/2004)|
|5.||Mayer, Emeran A: 4 articles (07/2007 - 10/2002)|
|6.||Talley, N J: 4 articles (06/2007 - 04/2001)|
|7.||Ameen, Vanessa Z: 4 articles (01/2005 - 08/2004)|
|8.||Lembo, Anthony: 3 articles (04/2012 - 01/2003)|
|9.||Heath, Amy T: 3 articles (08/2007 - 08/2004)|
|10.||Koch, K M: 3 articles (07/2004 - 04/2001)|
|1.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
06/01/2002 - "The third report of two placebo-controlled studies indicated significant improvement with alosetron on most domains of Irritable Bowel Syndrome Quality of Life Questionnaire. "
02/01/2003 - "Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials."
01/01/2000 - "A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome."
09/01/1998 - "Alosetron increases the compliance of the colon to distension, and could thereby contribute to changes in perception of colonic distension and improvement in the symptoms of irritable bowel syndrome."
06/01/2010 - "The objective of this study is to evaluate the incremental net benefit (INB) framework for undertaking quantitative benefit-risk assessment by performing a quantitative benefit-risk analysis of alosetron for the treatment of irritable bowel syndrome from the patients' perspective. "
06/01/2005 - "Alosetron is more effective than placebo in women with diarrhea-predominant IBS, although its use should be limited to patients who have failed conventional therapy because of its adverse event profile."
11/01/2004 - "To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i.e., bowel urgency at least 10 of 14 days during screening). "
07/23/2001 - "Forty-three percent of alosetron-treated patients with diarrhea-predominant IBS reported adequate relief for all 3 months compared with 26% of placebo-treated patients (P<.001; percentage point difference = 17; 95% confidence interval, 8.0-25.4). "
08/01/2007 - "A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS."
12/15/2005 - "Trials using alosetron showed a clinically significant, although modest, gain over placebo, but it is indicated only for women with severe diarrhea-predominant symptoms or for those in whom conventional treatment has failed. "
05/01/2008 - "A previous meta-analysis of 6 randomized controlled trials of the 5-HT(3)-receptor antagonist alosetron found that this agent was associated with global improvement in symptoms, pain, and discomfort in patients with IBS. "
08/01/2007 - "Alosetron 0.5 mg and 1 mg once daily as well as 1 mg twice daily are effective in providing global improvement in IBS symptoms, adequate relief of IBS pain and discomfort, and improvement in bowel symptoms in women with severe d-IBS. "
03/25/2000 - "Alosetron was well tolerated and clinically effective in alleviating pain and bowel-related symptoms in this population of women with IBS."
05/01/2008 - "In the 6 trials included in the analysis of adequate relief of IBS pain and discomfort, there was also a significant difference in favor of alosetron (RR = 1.31; 95% CI, 1.20-1.43; P < 0.001). "
01/01/2000 - "In Phase II trials, alosetron, 1 mg b.i.d., resulted in a greater proportion of non-constipated IBS patients reporting adequate relief of pain and discomfort, as well as improvement of bowel symptoms, frequency, urgency and stool consistency when compared with placebo. "
|4.||Abdominal Pain (Pain, Abdominal)
07/01/2006 - "Alosetron, a 5-HT(3) antagonist, is superior to placebo for reducing bowel frequency, improving stool consistency, and relieving abdominal pain in women with D-IBS. "
03/01/2000 - "In clinical trials in patients with IBS, alosetron 1 mg twice daily was effective in relieving abdominal pain and discomfort. "
08/01/2006 - "Alosetron improved abdominal pain and discomfort and stool consistency in both female and male patients, but it did not improve other symptoms (sense of urgency, stool frequency and bloating) in male patients. "
11/01/2003 - "Studies involving healthy volunteers and IBS patients have demonstrated a beneficial effect of treatment with alosetron on global IBS symptoms, abdominal pain and discomfort, altered bowel function as well as improvement of quality of life (QOL). "
01/16/2013 - "For example, alosetron displays efficacy in the treatment of multiple symptoms, including abdominal pain, discomfort, urgency, stool frequency and consistency. "
07/01/2011 - "Despite the small number of deaths associated with alosetron in patients with complications of constipation and because of the ongoing requirement to prescribe alosetron under a risk management plan, misconceptions persist regarding the definition, incidence, severity and outcome of IC in clinical trials and the postmarketing setting. "
01/01/2000 - "Alosetron was well-tolerated in all studies, with the most frequently recorded adverse event being constipation. "
05/01/2014 - "For IBS-D, alosetron and tricyclic anti-depressants caused constipation among a respective 16.9% and 13.0% resulting in a FNV of -3.6 and -0.5 percentage units. "
09/01/2012 - "The incidence of adverse events with alosetron was low with constipation being the most commonly reported event. "
05/01/2008 - "constipation was the most frequently reported adverse event associated with alosetron therapy. "
|1.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|4.||Serotonin 5-HT3 Receptor Antagonists
|5.||Antidepressive Agents (Antidepressants)
|6.||Serotonin (5 Hydroxytryptamine)
|2.||Drug Therapy (Chemotherapy)